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Abstract
Children and adolescents living with Hiv (CALHiv) in sub-Saharan Africa experience significant morbidity and alarmingly 
high mortality rates due to critical gaps in the Hiv care cascade, including late diagnosis and initiation of treatment, as 
well as poor retention in care and adherence to treatment. interventions to strengthen the adult Hiv care cascade may 
not be as effective in improving the cascade for CALHiv, for whom specific strategies are needed. Particular attention 
needs to be paid to the contexts of sub-Saharan Africa, where more than 85% of the world’s CALHiv live. implementing 
the ‘treat all’ strategy in sub-Saharan Africa requires dedicated efforts to address the unique diagnosis and care needs 
of CALHiv, in order to improve paediatric and adolescent outcomes, prevent viral resistance and reduce the number of 
new Hiv infections. we consider the UNAiDS 90-90-90 targets from the perspective of infants, children and adolescents, 
and discuss the key challenges, knowledge gaps and urgent research priorities for CALHiv in implementation of the 
‘treat all’ strategy in sub-Saharan Africa.
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Introduction
The ambitious UNAiDS 90-90-90 targets intend that, by 2020, 
90% of people living with Hiv are diagnosed, 90% of those who 
are diagnosed are on antiretroviral therapy (ART), and 90% of 
those on ART are virally suppressed [1]. Central to these targets 
is achieving them for all people living with Hiv, which requires 
particular attention to vulnerable groups who remain furthest 
from reaching them [2]. Children and adolescents living with Hiv 
(CALHiv) continue to experience alarmingly high mortality and 
poorer outcomes in the Hiv care cascade compared to adults 
[2]. CALHiv have much to gain from the ‘treat all’ strategy, and 
they also have specific needs that must be addressed to ensure 
its successful implementation [3–6]. Here, we consider the 90-90-
90 targets from a paediatric perspective, and discuss the key 
challenges, knowledge gaps and urgent research priorities in 
implementing the ‘treat all’ strategy in sub-Saharan Africa. This 
review is informed by systematic activities to set global Hiv research 
priorities undertaken by both the Collaborative initiative for Pae-
diatric Hiv education and Research (CiPHeR), and the international 
epidemiology Databases to evaluate AiDS (ieDeA), with adapta-
tion to incorporate current paediatric evidence and the input of 
stakeholders from sub-Saharan Africa [7].
Challenges throughout the HIV care cascade for 
infants, children and adolescents
UNAiDS estimates that there were approximately 1.8 million 
children living with Hiv (CLHiv, ages 0–14), and 1.8 million 
adolescents living with Hiv (ALHiv, ages 10–19) globally in 2017, 
of whom more than 85% lived in sub-Saharan Africa (Table 1) 
[8]. CALHiv experience complex challenges accessing Hiv testing 
and care and adhering to ART, resulting in late diagnoses, poor 
viral suppression and high mortality [2]. while deaths have declined 
substantially among CLHiv, there were 110,000 deaths in this 
group in 2017 [8]. Meanwhile, ALHiv have been the only age 
group with increasing deaths in recent years, despite a massive 
scale-up in the availability of ART [8].
The epidemic among infants and children
Although vertical transmission of Hiv has significantly decreased 
in recent years, global ART coverage for prevention of vertical 
transmission is currently at 80%, and in 2017 there were 180,000 
new paediatric infections [8]. infants under 12 months and later 
24 months of age were the first to have a recommendation for 
universal treatment in 2008 and 2010, respectively, and they 
have the most dramatic benefit from immediate treatment [9]. 
in this context, current gaps in infant diagnosis and treatment 
are particularly concerning, and contribute to high early Hiv-
related mortality before the age of 2 years [10]. Paediatric diag-
nosis is frequently delayed, with the majority of CLHiv in low- and 
middle-income countries initiating ART at a stage of advanced 
immunodeficiency [11–13]. Late perinatal diagnosis sets the stage 
for advanced illness and medical vulnerability, inadequate immune 
recovery once ART is initiated, development of opportunistic 
infections, and neurological and inflammatory consequences of 
uncontrolled Hiv [14]. Beyond diagnosis, significant proportions 
of CLHiv are not accessing ART or achieving viral suppression 
[2].
The epidemic among adolescents
Hiv is a leading cause of death among adolescents in sub-Saharan 
Africa [15]. The number of ALHiv has been steadily increasing, 
composed of both adolescents who acquired Hiv vertically with 
long-standing infections and those with recently acquired Hiv 
[16–19]. it is estimated that ALHiv with vertically acquired 
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Table 1. UNAiDS estimates of children (ages 0–14) and adolescents (ages 10–19) living with Hiv in sub-Saharan Africa and globally, in 2017*
a. Children living with HIV
Number Percentage 
of global 
total (%)
Number 
of new 
infections 
(%)
Percentage 
of global 
total (%)
Number of 
AIDS 
deaths (%)
Percentage 
of global 
total (%)
Percentage 
of children 
with HIV on 
ART (%)
Percentage coverage 
of pregnant women 
receiving ART for 
PMTCT (%)
Sub-Saharan Africa 1,700,000 94.4 159,000 88.3 97,000 88.2 49.3 81.2
 east and Southern Africa 1,200,000 66.7 92,000 51.1 52,000 47.3 59.0 93.0
 west and Central Africa 500,000 27.8 67,000 37.2 45,000 40.9 26.0 48.0
Global 1,800,000 180,000 110,000 52.0 80.0
b. Adolescents living with HIV
Number Percentage 
of global 
total (%)
Number of 
new infections
Percentage of 
global total (%)
Percentage of new 
infections among 
females (%)
Number 
of AIDS 
deaths
Percentage of 
global total 
(%)
Sub-Saharan Africa 1,540,000 85.6 189,000 75.6 75.1 35,000 92.1
 east and Southern Africa 1,100,000 61.1 120,000 48.0 80.0 22,000 57.9
 west and Central Africa 440,000 24.4 69,000 27.6 66.7 13,000 34.2
Global 1,800,000 250,000 68.0 38,000
*Source: UNAiDS estimates – 2018. Available at: aidsinfo.unaids.org (accessed 24 July 2018).
infection make up a majority of this age group; however, there 
are limited available data disaggregated by mode of infection 
[19–21]. Among adolescents who recently acquired Hiv, two-
thirds are girls, as a result of factors including gender-based 
inequity and violence, lower Hiv education, age-disparate rela-
tionships and poverty [22,23]. Adolescence encompasses rapid 
physiological, developmental, familial and social changes, such 
that adolescents have specific, evolving needs and capacities 
(such as the ability to manage one’s own appointments, or to 
adhere to medications, or to make independent decisions about 
one’s own care) over these years that extend into young adult-
hood (ages 20–24)[24]. Adolescents have unique challenges in 
their Hiv care, including those related to access to testing and 
care, parental consent policies, adolescent disclosure, a shift from 
dependence on caregivers to independence in care, and transition 
to adult Hiv services [25–27]. Adolescent Hiv care is complicated 
by stigma, fear of Hiv status disclosure, mental health needs, 
and challenges experienced in family, school and clinic environ-
ments [27–30]. These factors are exacerbated by the settings of 
poverty and marginalisation in which many ALHiv live [31]. 
improvements to the ALHiv care cascade are urgently needed, 
not only to improve adolescent outcomes, but also to end the 
AiDS epidemic, via reduction of vertical and horizontal Hiv trans-
mission and prevention of viral resistance.
Target: 90% of people living with  
HIV diagnosed
Missed opportunities to diagnose infants and children
while perinatal Hiv infection is associated with high mortality in 
infancy [10], there is a cohort of survivors of untreated perinatal 
Hiv infection who are not diagnosed until reaching advanced 
illness, even into their second decade of life [16–18]. Current 
models estimate that two-thirds of infants acquire Hiv in utero 
or at delivery, and experience rapid progression of illness, with 
a median survival of 1 year; the remaining infants acquire Hiv 
during breastfeeding and are projected to experience slower disease 
progression, with a median survival to age 14 without treatment 
[32–34]. Many perinatally infected children are not identified, 
due to missed maternal Hiv diagnoses, gaps in coverage of early 
infant diagnosis, and failures to diagnose children outside pre-
vention of vertical transmission programmes [11,35]. wHO 
recommends testing all Hiv-exposed infants at 4–6 weeks of 
age, but early infant diagnosis coverage remains a challenge, 
with huge geographical heterogeneity in sub-Saharan Africa [36]. 
in 2015, only 49% of Hiv-exposed infants globally had a viro-
logical Hiv diagnosis within the first 2 months of life [2]. An 
analysis of Hiv programmes in six African countries and Haiti 
found that the proportion of Hiv-exposed infants tested for Hiv 
within 6 weeks of birth surpassed 50% only in South Africa and 
Zambia, and mean result turnaround times ranged from 22 to 
38 days [37]. Moreover, there are missed opportunities to diag-
nose children seen in other healthcare settings, and a high potential 
yield for identifying children with previously undiagnosed Hiv, 
particularly in inpatient and nutrition centres [16,35,38]. A study 
of primary school students found a significant burden of undi-
agnosed Hiv, and important barriers to testing, including parental 
fears of ‘unmasking’ their own status and of the child experiencing 
stigma [39]. There is an urgent need to scale up and optimise 
provider-initiated Hiv testing adapted to age, integrated with 
prevention programmes, Hiv, and maternal and child health pro-
grammes, and paired with timely treatment initiation.
Most ALHiv have not been diagnosed
inadequate testing currently presents a significant gap in the 
adolescent care cascade, and it precludes the subsequent steps 
of engagement in care and successful treatment. Demographic 
and health survey data from Congo (Brazzaville), Mozambique, 
Nigeria and Uganda, including 23,367 respondents aged 15–24 
years, showed that 36.5% overall – and only 26.5% of 15–19-year-
olds – had ever tested for Hiv [22]. As a result of low testing 
uptake, it is estimated that a majority of ALHiv have not been 
diagnosed [2]. Population-based Hiv impact Assessments (PHiA) 
conducted in Malawi, Zambia and Zimbabwe found that only 
46% of youths living with Hiv (YLHiv, ages 15–24) were aware 
of their Hiv status, compared to 65% of 25–34-year-olds, and 
78% of 35–59-year-olds [2,40–42]. Among participants in the 
SeARCH study in Kenya and Uganda, only 50% of YLHiv were 
aware of their status at baseline, compared to 67% of older 
adults [43]. while there are few data on testing in the younger, 
10–14-year-old adolescents, a study from Zimbabwe found that 
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they were less likely to be offered testing than children aged <7 
years, despite the burden of undiagnosed perinatal infection in 
this group [18,44]. in a study from Botswana, in comparison to 
older age groups, 10–14-year-olds diagnosed with TB were least 
likely to have an Hiv test; however, of those tested, 52% were 
Hiv-infected [45].
important barriers to adolescent Hiv testing include low perceived 
risk of infection, fear of stigma, financial costs and gender inequal-
ity [46]. These may be particularly significant for younger ado-
lescents. in a mixed-methods study from Zimbabwe, a major 
reason for providers not offering Hiv tests to children aged 6–15 
was concern about the suitability of the accompanying caregiver 
to provide consent [44]. This is a significant challenge in countries 
of sub-Saharan Africa with generalised Hiv epidemics, where a 
high proportion of children are AiDS orphans, adult migration 
for work is common, children are cared for by multiple relatives, 
legal documentation of guardianship is unusual, and policies 
around consent for Hiv testing are varied, without clear guidance 
on who may give consent [44].
Target: 90% of diagnosed people living with 
HIV on sustained ART
The treatment gap for infants and children
ART is lifesaving for CALHiv. Highlighting the urgency of early 
infant diagnosis, linkage to care and prompt treatment, initiation 
of ART before 3 months of age potentially reduces child Hiv-
associated mortality by 75% [9,47]. Current estimates are that 
only 52% of CLHiv globally are receiving ART; 59% in eastern 
and southern Africa, and 26% in western and central Africa [8]. 
in an analysis of ieDeA global cohort data, including 135,479 
CALHiv aged 0–19 (over 95% from sub-Saharan Africa), during 
2004–2015, 20% were lost to follow-up (LTFU) prior to ART 
initiation, possibly representing undocumented mortality [48]. 
infants had 66% cumulative incidence of ART initiation at 24 
months (95% confidence interval [Ci] 66–67%); and infants and 
ALHiv ages 15–19 had the lowest ART initiation of all age groups 
[48]. ART initiation was lowest in sub-Saharan Africa [48]. Bar-
riers to high ART coverage among CLHiv include delayed diagnosis, 
limited health worker capacity and poor supply chain for paediatric 
Hiv commodities [3].
The challenge of retention among adolescents
Data from across sub-Saharan Africa have demonstrated poor 
ART initiation and retention among ALHiv [43,48–51]. in the 
SeARCH study, only 64% of previously diagnosed YLHiv were 
on ART at baseline, compared to 81% of older adults [43]. in 
the analysis of ieDeA paediatric cohorts, the cumulative incidence 
of ART initiation was lowest among ALHiv ages 15–19 years, 
with 62% initiating ART by 24 months (95% Ci 62–63%) [48]. 
Older adolescents were most likely to be LTFU, as has also been 
reported in studies across sub-Saharan Africa [48,49,52–54]. 
This finding might reflect that the 15–19-year-old group included 
those with more recent infection, as ART eligibility at enrolment 
was correlated with cumulative ART initiation [48]. Adopting the 
‘treat all’ strategy could improve retention among ALHiv who 
were previously not ART-eligible; however, age- and context-
specific strategies for improving retention are urgently needed 
to reach 90-90-90 targets [43,48,55].
Complex barriers to retention for CALHiv
CALHiv experience significant barriers to retention. A cohort 
study from South Africa found that only 66% of CLHiv were 
retained in care, with greater attrition in recent years and in 
infants [56]. A case–control study of paediatric patients in Bot-
swana found that factors associated with LTFU included: age <5 
years, advanced Hiv disease, greater immunosuppression and 
not receiving ART [57]. Nearly half of the LTFU patients had 
dropped out of care after just one clinic visit [57]. early attrition 
from care has been reported in other studies of CALHiv, high-
lighting the need to engage patients on their initial presentation 
to Hiv care [48,50,57,58]. Barriers cited by parents of LTFU 
CLHiv included beliefs that the child was well, fear of stigma 
and disclosure issues [57]. Barriers to retention for ALHiv include 
stigma, illness or death of family members, mental health chal-
lenges, substance abuse, poverty, and factors of clinic and school 
environments [27,30,38,59–61]. Facilitators to retention for 
CALHiv include social and family support, as well as future ori-
entation and self-sufficiency of adolescents [27,29,60–62].
Target: 90% of people receiving ART with 
suppressed viral load
Gaps in viral suppression among infants and children
CALHiv have lower viral suppression compared to adults[52,63–
66]. viral suppression is critical to achieving optimal treatment 
outcomes, including neurocognitive and growth outcomes [63]. 
Meanwhile, there is a need for expanded access to routine viral 
load testing. At present, population-based estimates for paediatric 
viral suppression are lacking, as are data to identify factors associ-
ated with virological failure. A South African study found that 
only half of retained children achieved viral suppression [56].
emerging data highlight reduced efficacy of specific ART regimens 
in CALHiv. A South African study demonstrated lower viral sup-
pression for CLHiv when abacavir was used as part of a first-line 
ART regimen, compared to older, stavudine-based regimens [67]. 
with shifts in ART regimens, potential impacts on efficacy and 
adherence should be considered [67]. A lack of appropriate pae-
diatric formulations remains a critical barrier [68]. There are also 
significant challenges identifying virological failure and Hiv resist-
ance in CLHiv, and providing second- or third-line regimens for 
lifelong ART [7].
Challenges for viral suppression among adolescents
Among YLHiv on ART, the PHiA surveys found that only 79% 
were virally suppressed, compared to 90% of adults. Given gaps 
earlier in the cascade, this translated to only 30% of all YLHiv 
with viral suppression; far below the target of 73% [2]. Similarly, 
in the SeARCH study, only 26% of all YLHiv had viral suppres-
sion at baseline [43]. in a study of adolescents who acquired Hiv 
perinatally in global cohorts, 65% of African ALHiv experienced 
viral suppression at last visit, where viral load was available [20].
Adolescents have significant, complex challenges adhering to 
ART. A meta-analysis estimated that 62% of ALHiv and YLHiv 
globally are >95% adherent to ART, with higher adherence in 
Africa and Asia, although there was variability in measures of 
adherence used [69]. A study of Tanzanian ALHiv found an asso-
ciation between mental health difficulties with both stigma and 
decreased adherence [70]. Among ALHiv in Malawi, barriers 
independently associated with missed doses in the past week 
included alcohol use, missed clinic appointments, violence in the 
home and poor treatment self-efficacy [71].
Research gaps and priorities for CALHIV
Achieving the 90-90-90 targets for CALHiv will require signifi-
cant improvements along the Hiv care cascade, tailored to the 
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specific needs of CALHiv. CALHiv may be the furthest behind in 
reaching the 90-90-90 targets, yet the successful implementation 
of the ‘treat all’ strategy will have immense potential benefits 
for this population [63]. earlier diagnosis, initiation of ART and 
improved quality of care to achieve viral suppression will be life-
saving for CALHiv. improvements to the adolescent care cascade 
will not only reduce their mortality, but also: reduce transmission 
to partners, reduce vertical transmission, and foster a healthy 
productive adulthood, as well as improving maternal and child 
health outcomes. Linkage of testing to prevention services could 
have the additional benefit of promoting uptake of prevention 
measures, including pre-exposure prophylaxis (PreP) [4]. improved 
estimates of the CALHiv epidemic are needed to guide the global 
response and tailor services to this group. Research is urgently 
needed to identify cost-effective interventions at each stage of 
the care cascade and to learn how to implement these at scale. 
interesting and informative examples of work in these areas are 
highlighted.
The need for improved estimates for the paediatric and 
adolescent epidemics
Despite the burden of Hiv among children and adolescents glob-
ally, there are significant gaps in the empirical data that guide 
the response to the epidemic. There is a critical need for accurate 
estimates for CALHiv, regarding: the number and proportion 
undiagnosed; timeliness in achieving care cascade stages; treat-
ment outcomes, including Hiv drug resistance and outcomes 
after LTFU and transfer-out; and definitive data on mortality. 
There is a need for disaggregation of data by 5-year age groups, 
sex and mode of infection. There is also a need for behavioural 
surveys to be designed for use among adolescents and disag-
gregated by age, particularly to address ALHiv from key popula-
tions [72].
importantly, it is not currently known what proportion of ALHiv 
experienced vertical or horizontal routes of infection, and these 
groups may have different needs and require different responses 
for successful diagnosis and treatment [20,21,72]. To describe 
outcomes among likely perinatally infected adolescents, a recent 
analysis of 12 global paediatric cohorts evaluated ALHiv who 
enrolled in care before age 10 years and were not known to have 
horizontally acquired Hiv [20]. Rates of LTFU and transfer-out 
were significantly higher among African ALHiv compared to other 
regions, and were likely to include unascertained mortality [20]. 
Given increasing Hiv-associated mortality among adolescents, 
understanding the causes of ALHiv mortality is critically important.
Adapting Hiv diagnosis and linkages to care for  
paediatric populations
Addressing gaps in paediatric and adolescent diagnosis and linkage 
to care will require an evaluation of appropriate context-specific 
interventions, their effectiveness, and their implementation within 
healthcare systems and service delivery models, including integra-
tion of Hiv care with prevention of vertical transmisson, maternal 
child health programmes, and paediatric and adolescent healthcare 
services. Testing innovations, including rapid point-of-care Hiv 
testing for infant diagnosis and expansion of paediatric testing 
at other entry points to the health system, may enhance timely 
diagnosis of Hiv in CALHiv and decrease the time to ART initia-
tion [73]. Modelling studies evaluating routine Hiv testing at 
birth (to diagnose in utero infection requiring urgent ART), in 
addition to currently recommended testing at 6 weeks, demon-
strate improved outcomes, including ART initiation before 3 months 
and decreased infant mortality, and cost-effectiveness [74,75]. 
A study in Botswana showed promise for targeted neonatal testing 
to diagnose in utero transmission in high-risk infants [76]. There 
is potential for community-based interventions to enhance uptake 
of testing and linkage to care. A nested cohort study in Nigeria 
evaluated a church congregation-based intervention designed to 
increase uptake of Hiv testing among pregnant women, and 
found that early infant diagnosis was higher and Hiv vertical 
transmission was lower among participants compared to baseline 
[77]. The SeARCH trial of a community-based testing and treat-
ment programme achieved an increase from 50.3% to 86.5% of 
YLHiv being aware of their status; although viral suppression 
remained suboptimal due to reported difficulties with stigma and 
care logistics while at boarding school [43].
The wHO has developed guidelines for adolescent Hiv testing 
and care directed at policymakers and programme managers, 
including recommendations to revisit policies around age of consent 
for Hiv testing and facilitating access to care for ALHiv, particu-
larly those from key populations [78]. There is a need to study 
service delivery interventions and care models to improve access 
to testing (and repeat testing), linkage to care, and ART initiation 
with attention to the needs of ALHiv [7]. in South Africa, imple-
mentation of an integrated Youth Centre incentivising utilisation 
of services resulted in greater numbers of young adolescents 
(ages 12–15 years), particularly males, testing for Hiv; among 
older adolescents, more individuals tested at the community clinic 
[79]. A systematic review found that provider-initiated inpatient 
Hiv testing and home-based Hiv testing of children and ado-
lescents appear to have high acceptability [80]. Home-based 
testing in the PopART trial was accepted by 80% of adolescents 
aged 15–19, and the number of adolescents who knew their 
status increased from 28% to 89% [81]. Self-testing strategies 
for adolescents have demonstrated high uptake [82], acceptability 
[83] and cost-effectiveness [84]. Targeted strategies are urgently 
needed for adolescents from key populations for increased and 
repeated testing, enhanced linkage to Hiv care for all testing 
positive, and prevention services for those testing negative, includ-
ing PreP [85,86].
integrating tailored support into service delivery
More research around interventions and service delivery models 
to improve CALHiv outcomes in the care cascade, including linkage 
to care and retention on ART, would guide service delivery 
[3,5,7,27,87]. This should specifically include models to integrate 
Hiv care into other health systems, including maternal child health 
clinics and general paediatric and adolescent health services. 
Psychosocial support strategies, such as family support and inter-
ventions, disclosure support, and stigma reduction in clinical, 
school and community settings, should be pursued7. integrating 
interventions for mental health issues and substance use disorders 
into Hiv care would mitigate the significant mental health barriers 
CALHiv face in accessing and continuing in care [28,70].
Though a recent systematic review found that few interventions 
have been studied to improve retention of ALHiv, promising 
potential strategies include education and counselling, peer inter-
ventions, financial interventions, clinic accessibility and specific 
adolescent-friendly services [87]. There is a need for rigorous, 
larger studies to evaluate these potential areas of intervention 
[87]. A few observational studies have evaluated the impact of 
adolescent-friendly services on retention in care, with mixed results 
[27,50,58,88,89]. Potential reasons for this are that adolescent-
friendly services may be insufficient to mitigate the complex 
challenges to retention for many ALHiv, or that ALHiv become 
LTFU before engaging effectively with these interventions [27]. 
Differentiated care models have shown promise in improving adult 
engagement with Hiv services, but it is less clear how effective this 
approach will be for ALHiv [87]. in Zimbabwe, CALHiv managed 
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within a decentralised Hiv care model experienced encouraging 
retention in care, though only 64% achieved viral suppression 
[64]. importantly, strategies are needed to specifically address 
sexual and reproductive health outcomes of ALHiv, pregnant 
ALHiv and ALHiv from key populations, and there are few studies 
in these areas [85,86,90,91]. More data on strategies to support 
ALHiv to successfully transition to adult Hiv services are criti-
cally needed to reduce attrition from care at this stage [92,93].
improving viral suppression and treatment outcomes  
for CALHiv
There is a very small evidence base for interventions to improve 
paediatric and adolescent adherence to ART, and consequently, 
viral suppression [85,86,91,94]. A systematic review of ART 
adherence interventions for ALHiv ages 13–24 found that, out 
of a few studies meeting inclusion criteria, most were small, 
unreplicated pilot studies conducted in the USA [94]. evidence 
was found for a phone-based adherence monitor intervention, 
and for individual and family counselling, to improve viral sup-
pression [94]. The BReATHeR trial demonstrated that a ‘weekends-
off’ efavirenz-based ART regimen in participants aged 8–24 on 
first-line ART was non-inferior to a continuous regimen, and had 
a better safety profile, presenting a treatment option aiming to 
lessen treatment fatigue, meet lifestyle needs and facilitate adher-
ence [95]. while the introduction of dolutegravir offers promise 
for ALHiv, given its once-daily dosing, a high genetic barrier for 
resistance, and lack of cross-resistance to first-generation integrase 
inhibitors, recent data indicating possible elevated risk of neural 
tube defects in infants following exposure during conception 
may impact how it is used in adolescents [96]. investigational 
long-acting injectable formulations of ART may have potential 
future use to facilitate adherence to treatment [97].
Other priority research areas include evaluating the impacts of 
Hiv infection and of ART on paediatric and adolescent clinical 
outcomes, including virological outcomes, the potential for func-
tional cure with very early ART in infancy, and development of 
opportunistic infections and non-communicable diseases [7]. 
efforts to improve prevention, diagnosis and clinical management 
of TB and other co-infections will also be critical to improving 
outcomes.
Conclusions
Dedicated efforts are needed to meet the context- and age-
specific needs of CALHiv, including a focus on critical research 
priorities. Targeted research to strengthen the child and adolescent 
Hiv care cascades in the implementation of ‘treat all’ will translate 
to improved outcomes for these children and adolescents, fol-
lowed by transitions to healthy adulthoods.
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